Executive Management

Jenna brings two decades of experience in finance from the pharmaceuticals industry. Prior to joining Cornerstone, she spent 10 years on the research and development finance team at Daiichi Sankyo. Jenna grew her role from back-office support into a true business partner, as she integrated herself as a key member of the clinical projects team. She was instrumental in transforming the finance department at Daiichi Sankyo. Given her experience and strong technical expertise, Jenna will ensure that Cornerstone allocates its financial resources most efficiently and productively, allowing the company to focus on its top priority; the patients it serves. In her role she will also act as head of IT overseeing the technical infrastructure within an organization, determining business requirements for IT systems, and eliminating security risks. In addition, she will take on the role of Administrative Officer for Cornerstone, responsible for the administrative and operational of the organization, overseeing daily operations.

Dr. Shorr has a 40-year track record in drug discovery from concept through approval and market launch. As Cornerstone’s Chief Scientific Officer, Dr. Shorr’s primary focus is on the discovery and development of safe and effective novel drugs and delivery technology. He has previously served as VP of Science and Technology at Enzon Pharma, VP of Science and Technology and Chief Scientist at United Therapeutics, and Associate Director of Molecular Pharmacology at SmithKline Beecham. At Enzon, Dr. Shorr was responsible for co-development with Schering-Plough of the blockbuster drug, PEG INTRON A, for the treatment of hepatitis and certain forms of melanoma. Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters and conference proceedings and has more than 150 inventions with more than 300 issued and pending patents worldwide. He earned his Ph.D. from the University of London, and a DIC from the University of London Imperial College of Science and Technology.

Dr. Pardee is a Professor of medicine and the Director of the Leukemia Program at the Comprehensive Cancer Center of Wake Forest Baptist Medical Center. He heads an NCI-funded research program focused on the role of cellular metabolism in cancer cell survival and resistance to therapy as well as novel therapeutics. Dr. Pardee has played a lead role in the development of the novel metabolism-targeting agent CPI-613^® (devimistat). He earned his M.D. and his Ph.D. from SUNY Buffalo.

Mike is a strong entrepreneurial leader who over the years spearheaded multiple departments at Cornerstone Pharmaceuticals, including Quality Assurance, Manufacturing and CMC. Over his career, he worked with innovative medicine organizations, like Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, resulting in commercialization of leading products: Praluent, Eylea, Kavzara, Dupixent, Onpattro and other. Mike holds a BioMedical Engineering degree and M.B.A. from University of Illinois at Chicago. He also achieved RAC (US & Global), Six Sigma and PMP certifications.